MDMarta de Oliveira Domingos

Marta de Oliveira Domingos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta de Oliveira Domingos has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    O26 Polysaccharides as Key Players in Enteropathogenic E. coli Immune Evasion and Vaccine Development

    by Thiago Jordão da Silva Lemos, Herbert Guimarães de Sousa Silva, José Osvaldo Previato, Lucia Mendonça-Previato, Elisangela Oliveira de Freitas, Angela Silva Barbosa, Marcia Regina Franzolin, Luis Fernando dos Santos, Bruna de Sousa Melo, Geovana Ferreira dos Anjos, et al.

    Enteropathogenic Escherichia coli (EPEC) produce a capsule of polysaccharides identical to those composing the O-antigen polysaccharide of its LPS (lipopolysaccharide) molecules. In light of this, the impact of O26 polysaccharides on the immune evasion mechanisms of capsulated O26 EPEC compared to non-capsulated enterohemorrhagic Escherichia coli (EHEC) was investigated. Our findings reveal that there was no significant difference between the levels in EPEC and EHEC of rhamnose (2.8:2.5), a molecule considered to be a PAMP (Pathogen Associated Molecular Patterns). However, the levels of glucose (10:1.69), heptose (3.6:0.89) and N-acetylglucosamine (4.5:2.10), were significantly higher in EPEC than EHEC, respectively. It was also observed that the presence of a capsule in EPEC inhibited the deposition of C3b on the bacterial surface and protected the pathogen against lysis by the complement system. In addition, the presence of a capsule also protected EPEC against phagocytosis by macrophages. However, the immune evasion provided by the capsule was overcome in the presence of anti-O26 polysaccharide antibodies, and additionally, these antibodies were able to inhibit O26 EPEC adhesion to human epithelial cells. Finally, the results indicate that O26 polysaccharides can generate an effective humoral immune response, making them promising antigens for the development of a vaccine against capsulated O26 E. coli.


  • Open Access

    Characterization of O26 Enteropathogenic E. coli and Its Impli-Cation for Vaccine Development

    by Thiago Jordão da Silva Lemos, Herbert Guimarães de Sousa Silva, José Osvaldo Previato, Lucia Mendonça-Previato, Elisangela Oliveira de Freita, Angela Silva Barbosa, Marcia Regina Franzolin, Luis Fernando dos Santos, Bruna de Sousa Melo, Geovana Ferreira dos Anjos, et al.

    O26 enteropathogenic Escherichia coli (EPEC), possesses a unique pseudocapsule composed of polysaccharides identical to the O antigen in their lipopolysaccharide (LPS) membrane. Therefore, the impact of O26 polysaccharides on the immune evasion mechanisms of capsulated O26 EPEC was investigated. Our findings reveal that the concentration of GlcNAc, an immunodominant unit of O26 polysaccharides capable of activating the MBL (Mannose Biding Lecting) pathway of the complement system, was found to be lower in capsulated EPEC O26 compared to naked shiga toxin-producing E. coli (STEC) O26 strain. It was noted that, unlike the naked STEC strain, the capsulated EPEC O26 strain was protected against lysis by the alternative pathway of the com-plement system by inhibiting C3b adhesion to its bacterial surface. Capsulated EPEC O26 strains were also able to avoid phagocytosis by macrophages. However, the immune evasion provided by the capsule was overcome in the presence of anti-O26 polysaccharide antibodies. Additionally, these antibodies were able to recognize O26 EPEC in the presence of biofilm and inhibit their adhesion to human epithelial cells. Overall, the results indicate that the O26 polysaccharides can generate an effective humoral immune response, making them promising antigens for the de-velopment of a vaccine against capsulated O26 E. coli

  • Open Access

    Botulinum Toxin A Delivery via MMP Technique: An Emerging Therapeutic Approach for Frontal Fibrosing Alopecia

    by Simone Ramos Nogueira Guerra Neri, Marta de Oliveira Domingos, Nílceo Schwery Michalany, Alexandre Ozores Michalany, Celia Luiza Petersen Vitello Kalil

    Frontal Fibrosing Alopecia (FFA) is a disease of unknown etiology and pathogenesis whose prevalence has been increasing since its first description in 1994. With no cure, treatments only control the inflammatory process and disease progression, but do not reverse the changes induced by it. We report the case of a patient with early-stage FFA who underwent three monthly sessions of 30 units of Botulinum Toxin Type A administered by MMP® (Microinfusion of drugs through the skin) technique. The results showed a substantial improvement in the patient's clinical condition with inhibition of the inflammatory process and an evident increase in follicular density in the treated area.


  • Open Access

    Botulinum toxin A as an alternative treatment for folliculitis decalvans

    by Simone R.N.G. Neri, Marcia R. Franzolin, Celia Luiza Petersen Vitello Kalil, Nílceo S. Michalany, Alexandre O. Michalany, Marta O. Domingos


  • Open Access

    O55 Polysaccharides Are Good Antigen Targets for the Formulation of Vaccines against O55 STEC and Capsulated aEPEC Strains

    by Herbert Guimarães de Sousa Silva, Marcia Regina Franzolin, Geovana Ferreira dos Anjos, Angela Silva Barbosa, Luis Fernando dos Santos, Kaique Ferrari Miranda, Ronaldo Maciel Marques, Matilde Costa Lima de Souza, Roxane Maria Fontes Piazza, Marta de Oliveira Domingos

    The serogroup O55 of E. coli is composed of strains whose mechanisms of virulence are different from each other. Since the O55 polysaccharides are present in all E. coli O55 strains, and so are the polymers that compose the capsule of O55 atypical enteropathogenic E. coli (aEPEC), it was investigated whether anti-O55 antibodies were able to help the innate immune system to eliminate capsulated aEPEC and Shiga toxin-producing E. coli (STEC) belonging to the serogroup O55. The results demonstrate that the capsule of EPEC was able to inhibit the deposition of C3b on the bacterial surface and, as a consequence, their lysis by the alternative pathway of the complement system. However, in the presence of antibodies, the ability of the complement to lyse these pathogens was restored. It was also observed that macrophages were able to ingest EPEC and STEC, but they were only able to kill the ingested pathogens in the presence of antibodies. Anti-O55 antibodies were also able to inhibit aEPEC and STEC O55 adherence to human epithelial cells. In summary, the results demonstrated that the O55 polysaccharides have the potential to induce an effective humoral immune response against STEC and EPEC, indicating that they are good antigen targets to be used in vaccine formulations against these pathogens.


  • Open Access

    Escherichia coli Strains Responsible for Cystitis in Female Pediatric Patients with Normal and Abnormal Urinary Tracts Have Different Virulence Profiles

    by Marta de Oliveira Domingos, Silvio Marciano da Silva Junior, Wagner Milanello, Shirley Sizue Nakamura Nakano, Marcia Regina Franzolin, Luis Fernando dos Santos, Kamila Oliveira Nunes, Vaniky Duarte Marques, Waldir P. Elias, Herbert Guimarães de Sousa Silva, et al.

    The role of uropathogenic Escherichia coli (UPEC) in colonization and infection of female patients with anatomical and functional abnormalities of the urinary system is elusive. In this study, the phenotype, genotype and the phylogeny of UPEC strains isolated from the urine of pediatric female patients with cystitis of normal and abnormal urinary tract were determined. Multiplex PCR results demonstrated that 86% of the strains isolated from female patients with normal urinary tract (NUT), belonged to the phylo-groups B2 and D. Their prevalence decreased to 23% in strains isolated from patients with abnormal urinary tract (AUT). More of the isolates from AUT patients produced a biofilm on polystyrene and polyvinyl chloride (PVC), adhered to epithelial cells, and encoded pap and sfa genes than strains isolated from female patients with NUT. In contrast, a higher number of hemolysin-producing strains with serogroups associated with UPEC were isolated from patients with NUT. In summary, the results suggest that cystitis in female patients with NUT is associated with ExPEC, whereas cystitis in female patients with AUT is associated with pathogenic intestinal E. coli strains that have acquired the ability to colonize the bladder.


  • Open Access

    In Silico Prediction and Design of Uropathogenic Escherichia coli Alpha-Hemolysin Generate a Soluble and Hemolytic Recombinant Toxin

    by Bruna De Lucca Caetano, Marta de Oliveira Domingos, Miriam Aparecida da Silva, Jessika Cristina Alves da Silva, Juliana Moutinho Polatto, Fabio Montoni, Leo Kei Iwai, Daniel Carvalho Pimenta, Hugo Vigerelli, Paulo Cesar Gomes Vieira, et al.

    The secretion of α-hemolysin by uropathogenic Escherichia coli (UPEC) is commonly associated with the severity of urinary tract infections, which makes it a predictor of poor prognosis among patients. Accordingly, this toxin has become a target for diagnostic tests and therapeutic interventions. However, there are several obstacles associated with the process of α-hemolysin purification, therefore limiting its utilization in scientific investigations. In order to overcome the problems associated with α-hemolysin expression, after in silico prediction, a 20.48 kDa soluble α-hemolysin recombinant denoted rHlyA was constructed. This recombinant is composed by a 182 amino acid sequence localized in the aa542–723 region of the toxin molecule. The antigenic determinants of the rHlyA were estimated by bioinformatics analysis taking into consideration the tertiary form of the toxin, epitope analysis tools, and solubility inference. The results indicated that rHlyA has three antigenic domains localized in the aa555–565, aa600–610, and aa674–717 regions. Functional investigation of rHlyA demonstrated that it has hemolytic activity against sheep red cells, but no cytotoxic effect against epithelial bladder cells. In summary, the results obtained in this study indicate that rHlyA is a soluble recombinant protein that can be used as a tool in studies that aim to understand the mechanisms involved in the hemolytic and cytotoxic activities of α-hemolysin produced by UPEC. In addition, rHlyA can be applied to generate monoclonal and/or polyclonal antibodies that can be utilized in the development of diagnostic tests and therapeutic interventions.


  • Open Access

    A new class of antimicrobial molecules derived from kefir, effective against Pseudomonas aeruginosa and methicillin resistant Staphylococcus aureus (MRSA) strains

    by Vaniky Duarte Marques, Marcia Regina Franzolin, Sabri Saeed Sanabani, Hugo Vigerelli, Roxane Maria Fontes Piazza, Daniel Carvalho Pimenta, Tiago Venâncio, Irys Viana Neves, Herbert Guimarães de Sousa Silva, Daniella dos Santos Courrol, et al.

    Many studies have linked the antimicrobial properties of kefir with the presence of bacteriocins and organic acids. In the present work, results obtained from bacteriostatic and bactericidal studies, and from RP-HPLC, Mass Spectrometry and proton NMR analysis, show that a sample of milk kefir grains is able to produce an antimicrobial fraction, denoted FK-1000, composed of sugars and amino acids, predominantly polymers of alanine, doublets of tyrosine and phenylalanine. Since this fraction is a lyophilized product whose molecular profile is different from bacteriocins and simple carboxylic acids, its antimicrobial effect cannot be attributed to these molecules, or to alcohols or hydrogen peroxide. The fraction is bactericidal against weak-acid-resistant MRSA and weak-acid resistant P. aeruginosa at pH 5, and is bacteriostatic against both pathogens at pH 7. In combination formulation, the FK-1000 fraction is able to increase fivefold the effect of streptomycin against P. aeruginosa and it is not toxic to human epithelial cells at antimicrobial concentrations. 16 S rRNA microbiota analysis of antimicrobial-producing and non-producing kefir grains demonstrated that they are distinct. In summary, the results indicate that milk kefir grains can produce different classes of molecules with potent antibiotic activity against resistant bacteria.


  • The potential of Loxosceles gaucho spider venom to regulate Pseudomonas aeruginosa mechanisms of virulence

    by Marta de Oliveira Domingos, Irys Viana Neves, Hugo Vigerelli, Daniel Carvalho Pimenta, Bianca de Carvalho Lins Fernandes Távora, Thiago Jordão Lemos, Marcia Regina Franzolin, Vaniky Duarte Marques, Katia Cristina Barbaro